CONTEXT: While prostate-specific antigen testing and biopsy are the most conclusive ways for detecting prostate cancer, no clear-cut imaging technique exists for initial diagnosis and staging.
CONTEXT: While prostate-specific antigen testing and biopsy are the most conclusive ways for detecting prostate cancer, no clear-cut imaging technique exists for initial diagnosis and staging. A preliminary study led by Dr. David Schuster, director of nuclear medicine and molecular imaging at Emory University, analyzed the PET agent anti-fluorine-18 FACBC for these roles. The amino acid-based radiotracer (a synthetic L-leucine analog) is designed to have properties of optimal nonspecific binding and metabolism. Compared with FDG, which does not accumulate in prostate tumors, anti-F-18 FACBC shows little renal excretion.
RESULTS: Following an injection of anti-F-18 FACBC, nine patients with newly diagnosed prostate cancer were scanned with PET/CT. Subjects underwent 65 minutes of dynamic imaging of the pelvis followed by static whole-body imaging. Maximum standard uptake value, recorded in the right and left lobes of the prostate and within lymph nodes, peaked within six minutes after infusion and remained significantly higher for at least 50 minutes in primary and metastatic prostate carcinoma compared with benign regions in 14 of 16 lobes. Malignant sextants and nodes had significantly higher SUVmax than did benign regions, though the numbers in this pilot study were small.
Visual analysis often successfully identified the presence or absence of neoplasia. Four false positives associated with inflammation and four false negatives stemming from microscopic disease arose from interpretation of delayed images. Uptake was elevated for recurrent disease in the prostate bed, and associated nodal and skeletal metastases often appeared when indium-111 ProstaScint uptake was not evident.
IMAGE: Intense FACBC uptake, indicative of recurrent cancer, appears in small right common iliac nodes (left). Corresponding ProstaScint SPECT image of the same patient was negative for iliac lymph node involvement.
IMPLICATIONS: Pilot data suggest anti-F-18 FACBC will be an effective agent for imaging early prostate cancer compared with FDG-PET/CT or In-111 ProstaScint. Lymph imaging indicates it could help differentiate between prostatic and extraprostatic reccurrence, Schuster said. Following on these positive yet limited results, subsequent trials will examine more patients to develop a strategy for clinical imaging.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.